mTOR signaling pathway and mTOR inhibitors in cancer therapy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Hematology/Oncology Clinics of North America

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.hoc.2012.02.014PMID 22520976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kidney Cancer

  2016cited by this paper
• Phase II study of everolimus in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.

  2011cited by this paper
• Everolimus for advanced pancreatic neuroendocrine tumors.

  2011cited by this paper
• A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas

  2011cited by this paper
• Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

  2011cited by this paper
• Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies

  2011cited by this paper
• Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

  2011cited by this paper
• Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

  2011cited by this paper
• Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

  2011cited by this paper
• Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

  2011cited by this paper
• Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

  2011cited by this paper
• Targeted combinatorial therapy of androgen receptor in androgen-independent prostate cancer cells.

  2011cited by this paper
• Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

  2011cited by this paper
• Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma

  2010cited by this paper
• Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

  2010cited by this paper
• Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma

  2010cited by this paper
• Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.

  2010cited by this paper
• Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

  2010cited by this paper
• A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

  2010cited by this paper
• NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

  2010cited by this paper
• Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

  2010cited by this paper
• The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

  2010cited by this paper
• Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

  2010cited by this paper
• Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase II clinical trial.

  2010cited by this paper
• Prognostic role of p‐mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer

  2010cited by this paper
• Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

  2010cited by this paper
• mTOR regulation of autophagy

  2010cited by this paper
• Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab

  2010cited by this paper
• A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

  2010cited by this paper
• Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

  2010cited by this paper
• Incidence rates of exocrine and endocrine pancreatic cancers in the United States

  2010cited by this paper
• Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

  2009cited by this paper
• Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

  2009cited by this paper
• PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer

  2009cited by this paper
• Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

  2009cited by this paper
• Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma

  2009cited by this paper
• Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

  2009cited by this paper
• mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling

  2009cited by this paper
• A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

  2009cited by this paper
• Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer

  2009cited by this paper
• Regulation of mTOR Complex 1 (mTORC1) by Raptor Ser863 and Multisite Phosphorylation*

  2009cited by this paper
• Tumor suppressors and cell metabolism: a recipe for cancer growth.

  2009cited by this paper
• The LKB1–AMPK pathway: metabolism and growth control in tumour suppression

  2009cited by this paper
• Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

  2009cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009cited by this paper
• Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

  2009cited by this paper
• Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1

  2009cited by this paper
• Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival

  2008cited by this paper
• Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.

  2008cited by this paper
• Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab

  2008cited by this paper
• A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

  2008cited by this paper
• Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover.

  2008cited by this paper
• The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C

  2008cited by this paper
• mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).

  2008cited by this paper
• Current Management of Tuberous Sclerosis Complex

  2008cited by this paper
• Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma

  2008cited by this paper
• One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

  2008cited by this paper
• Rapamycin and mTOR kinase inhibitors

  2008cited by this paper
• Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

  2008cited by this paper
• P-TEN exciting years: from the cytosol to the nucleus and back to keep cancer at bay

  2008cited by this paper
• The PTEN–PI3K pathway: of feedbacks and cross-talks

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• The role of PTEN signaling perturbations in cancer and in targeted therapy

  2008cited by this paper
• FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome

  2007cited by this paper
• Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer

  2007cited by this paper
• Defining the role of mTOR in cancer.

  2007cited by this paper
• Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

  2007cited by this paper
• Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

  2007cited by this paper
• The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines.

  2007cited by this paper
• The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.

  2007cited by this paper
• Targeting the mTOR signaling network in cancer.

  2007cited by this paper
• A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500)

  2007cited by this paper
• Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

  2006cited by this paper
• Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer

  2006cited by this paper
• PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer

  2006cited by this paper
• Current development of mTOR inhibitors as anticancer agents

  2006cited by this paper
• Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.

  2006cited by this paper
• TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.

  2006cited by this paper
• Loss of PTEN is associated with progression to androgen independence

  2006cited by this paper
• PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.

  2006cited by this paper
• Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas.

  2006cited by this paper
• Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin.

  2005cited by this paper
• Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression

  2005cited by this paper
• Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

  2005cited by this paper
• Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.

  2005cited by this paper
• Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

  2005cited by this paper
• Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer.

  2005cited by this paper
• The coordinate regulation of the p53 and mTOR pathways in cells.

  2005cited by this paper
• Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

  2005cited by this paper
• Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer

  2005cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• HIF-1: the knowns and unknowns of hypoxia sensing.

  2004cited by this paper
• Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.

  2004cited by this paper
• Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

  2004cited by this paper

• Bioinformatics Approach to mTOR Signaling Pathway-Associated Genes and Cancer Etiopathogenesis

  2025cites this paper
• Discovery of indole- and quinolone-based inhibitors of the mTOR/Akt/Pi3K pathway for the potential treatment of autism and certain types of cancer.

  2025cites this paper
• Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.

  2024cites this paper
• Increased expression of REG3A promotes tumorigenic behavior in triple negative breast cancer cells

  2024cites this paper
• Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years.

  2024cites this paper
• mTORC1-Induced Bone Marrow-Derived Mesenchymal Stem Cell Exhaustion Contributes to the Bone Abnormalities in Klotho-Deficient Mice of Premature Aging

  2023cites this paper
• Molecular genetic abnormalities in patients with T-cell acute lymphoblastic leukemia: a literature review

  2022cites this paper
• Chloroquine Combined With Rapamycin Arrests Tumor Growth in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Dedifferentiated Liposarcoma

  2022cites this paper
• Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies

  2022cites this paper
• An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth

  2022cites this paper
• Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells

  2022cites this paper
• Metabolic Regulation of T cell Activity: Implications for Metabolic-Based T-cell Therapies for Cancer

  2022cites this paper
• NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)

  2022cites this paper
• Targeting PI3K/Akt/mTOR Pathway by Different Flavonoids: A Cancer Chemopreventive Approach

  2021cites this paper
• Delineating the Role of PI3K Signaling Pathway in the Stem Cell Therapeutics of ROS-Induced Carcinomas

  2021cites this paper
• LncRNA SOX2-OT/miR-30d-5p/PDK1 Regulates PD-L1 Checkpoint Through the mTOR Signaling Pathway to Promote Non-small Cell Lung Cancer Progression and Immune Escape

  2021cites this paper
• Anticancer potential of (-)-epicatechin in a triple-negative mammary gland model.

  2021cites this paper
• Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth

  2021cites this paper
• The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620

  2021cites this paper
• The incidence of mTOR marker in tracheal adenoid cystic carcinoma by immunohistochemical staining.

  2020cites this paper
• Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist

  2020cites this paper
• Wubeizi Ointment Suppresses Keloid Formation through Modulation of the mTOR Pathway

  2020cites this paper
• Quantitative proteomic analysis of the association between decreasing O-GlcNAcylation and metastasis in MCF-7 breast cancer cells

  2020cites this paper
• Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study.

  2020cites this paper
• Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter

  2019cites this paper
• In Vitro and In Vivo Study on the Effect of Lysosome-associated Protein Transmembrane 4 Beta on the Progression of Breast Cancer

  2019cites this paper
• Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.

  2019cites this paper
• mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro

  2019cites this paper
• OTT_A_195121 9669..9683

  2019cites this paper
• Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients

  2019cites this paper
• GNG7 silencing promotes the proliferation and differentiation of placental cytotrophoblasts in preeclampsia rats through activation of the mTOR signaling pathway

  2019cites this paper
• mTOR Cross-Talk in Cancer and Potential for Combination Therapy

  2018cites this paper
• Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment

  2018cites this paper
• Advances in Biochemistry and Biotechnology Reprogram Metabolism of Infiltrated T Cells in Tumor Microenvironment to Improve Immunotherapy Outcomes

  2018cites this paper
• Targeting mTORC 1 / 2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes

  2018cites this paper
• Knockdown of MAGEA6 Activates AMP-Activated Protein Kinase (AMPK) Signaling to Inhibit Human Renal Cell Carcinoma Cells

  2018cites this paper
• eIF4E Phosphorylation in Prostate Cancer

  2018cites this paper
• Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo

  2017cites this paper
• Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis

  2017cites this paper
• Anticancer effects of limonene and phosphatidylinositol 3- Kinase (PI3K) inhibitor combination in colon cancer cell lines

  2017cites this paper
• ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo

  2017cites this paper
• The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent

  2017cites this paper
• Modulation of Akt/mTOR Pathway Signaling by Chemoprevention

  2017cites this paper
• The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.

  2017cites this paper
• Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy

  2017cites this paper
• Expression of TGF-β1/mTOR signaling pathway in pathological scar fibroblasts

  2017cites this paper
• ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

  2017cites this paper
• Metformin and mTOR Inhibitors: Allies against Ovarian and Breast Cancers

  2017cites this paper
• Targeting mTORC1/2 with OSI‐027 inhibits proliferation and migration of keloid keratinocytes

  2017cites this paper
• Preclinical study of CC223 as a potential anti-ovarian cancer agent

  2017cites this paper
• Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite

  2017cites this paper
• Autophagy in kidney disease and aging: lessons from rodent models.

  2016cites this paper
• Everolimus in every day practice of metastatic renal cell carcinoma therapy – one center experience

  2016cites this paper
• Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent

  2016cites this paper
• The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors

  2016cites this paper
• Ketogenic Diet and Cancer-a Perspective.

  2016cites this paper
• Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma

  2016cites this paper
• Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells

  2016cites this paper
• TSC2 Deficiency Unmasks a Novel Necrosis Pathway That Is Suppressed by the RIP1/RIP3/MLKL Signaling Cascade.

  2016cites this paper
• Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent.

  2016cites this paper
• mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity.

  2016cites this paper
• Metformin induces degradation of mTOR protein in breast cancer cells

  2016cites this paper
• Metformin treatment decreases mTOR mRNA level in MCF-7 breast cancer cells

  2016cites this paper
• from rodent models Autophagy in kidney disease and aging : lessons

  2016cites this paper
• T-cell immunometabolism against cancer.

  2016cites this paper
• mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat.

  2016cites this paper
• Tudor-SN Regulates Milk Synthesis and Proliferation of Bovine Mammary Epithelial Cells

  2015cites this paper
• 12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF and HIF-1α in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling pathway.

  2015cites this paper
• Autophagy inhibition sensitizes KU-0063794-mediated anti-HepG2 hepatocellular carcinoma cell activity in vitro and in vivo.

  2015cites this paper
• Recognition and Management of Oral Mucosal Injury Caused by Mammalian Target of Rapamycin Inhibitors: A Case Series

  2015cites this paper
• Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo

  2015cites this paper
• Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions

  2015cites this paper
• Incidence and Risk of High-grade Stomatitis with mTOR Inhibitors in Cancer Patients

  2015cites this paper
• Signaling pathways and mechanisms of hypoxia‐induced autophagy in the animal cells

  2015cites this paper
• Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.

  2015cites this paper
• Novel molecular targets for urothelial carcinoma

  2015cites this paper
• Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.

  2015cites this paper
• Targeting the PI3K/AKT/mTOR Pathway in Cancer Cells

  2015cites this paper
• Molecular prognostic markers in renal cell carcinoma

  2015influential citation
• Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond.

  2015cites this paper
• DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.

  2015cites this paper
• The role of mTOR in SAF-1-mediated VEGF expression and breast cancer progression

  2015cites this paper
• The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells.

  2014cites this paper
• The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals.

  2014influential citation
• Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells.

  2014cites this paper
• PP242 Synergizes With Suberoylanilide Hydroxamic Acid to Inhibit Growth of Ovarian Cancer Cells

  2014cites this paper
• Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer

  2014cites this paper
• Sirolimus-related systemic thrombotic microangiopathy after renal transplantation.

  2014cites this paper
• Safety profile and treatment response of everolimus in different solid tumors: an observational study.

  2014cites this paper
• Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells

  2014cites this paper
• Calorie restriction and dietary restriction mimetics: a strategy for improving healthy aging and longevity.

  2014cites this paper
• Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer

  2014cites this paper
• Characterization of cellular abnormalities due to loss of TSC2

  2014influential citation
• Rapamycin‐resistant effector T‐cell therapy

  2014cites this paper
• Sunitinib resistance in renal cell carcinoma

  2014cites this paper
• mTOR and Regulation of Translation

  2014cites this paper
• Inhibiting protein clearance to induce cell death in tuberous sclerosis and pancreatic cancer

  2014cites this paper
• Mammalian target of rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor-1α.

  2014cites this paper
• Metformin Impacts the Prognosis of Cancer Patients with Type 2 Diabetes

  2014cites this paper
• Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.

  2014cites this paper